This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
While Lonza's biopharmaceutical business has taken off, tough
competition from cheap Asian competitors is eating away at its
exclusive synthesis business - meanwhile, the whole business is
being hit by rising raw material and...
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.
Chemicals firm Lonza has vowed to spend $200m (€160m) over the next
few years to expand in southern China, further limiting its
dependence on external suppliers of intermediates and active
pharmaceutical ingredients (APIs).
Swiss custom manufacturing firm Lonza has entered into a joint
venture with investment management company Bio*One Capital to built
a $250m (€210m) large-scale mammalian cell culture plant in
Singapore, underlying Lonza's confidence...
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Lonza is planning a major exansion of its peptides manufacturing
capacities at Visp, Switzerland, in response to what it said was
'the increased demand for peptide active pharmaceutical ingredients
Lonza has commissioned a new current Good Manufacturing
Practice-compliant facility for the production of microbially
derived biopharmaceuticals at its largest worldwide production
centre in Visp, Switzerland.
Switzerland's Lonza Group said yesterday that it will use a novel
process developed by US-based biocatalysis company Codexis for the
synthesis of a key chiral pharmaceutical compound used in one of
the world's major human...